TrovaGene Company Profile (NASDAQ:TROV)

About TrovaGene (NASDAQ:TROV)

TrovaGene logoTrovagene, Inc. (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics. It has ongoing clinical collaborations to demonstrate the ability to determine and monitor mutational status and response to therapy in lung, colon, pancreatic and skin cancer. It uses its molecular diagnostic technology for the detection of cell-free deoxyribonucleic acid (DNA) originating from diseased cell death that can be isolated and detected from urine, blood and tissue samples to develop disease management.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Diagnostic & Testing Substances
  • Sub-Industry: N/A
  • Symbol: NASDAQ:TROV
  • CUSIP: N/A
  • Web: www.trovagene.com
Capitalization:
  • Market Cap: $30.67 million
  • Outstanding Shares: 37,269,000
Average Prices:
  • 50 Day Moving Avg: $0.74
  • 200 Day Moving Avg: $0.87
  • 52 Week Range: $0.61 - $4.25
P/E:
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.000
Sales & Book Value:
  • Annual Revenue: $354,234.00
  • Price / Sales: 84.69
  • Book Value: $0.11 per share
  • Price / Book: 7.12
Profitability:
  • EBITDA: ($29,350,000.00)
  • Net Margins: -10,390.96%
  • Return on Equity: -201.07%
  • Return on Assets: -85.12%
Debt:
  • Current Ratio: 1.16%
  • Quick Ratio: 1.16%
Misc:
  • Average Volume: 625,514 shs.
  • Beta: 0.3
  • Short Ratio: 3.74
 

Frequently Asked Questions for TrovaGene (NASDAQ:TROV)

What is TrovaGene's stock symbol?

TrovaGene trades on the NASDAQ under the ticker symbol "TROV."

How were TrovaGene's earnings last quarter?

TrovaGene, Inc. (NASDAQ:TROV) announced its earnings results on Tuesday, May, 10th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.29) by $0.07. The company earned $0.12 million during the quarter, compared to analysts' expectations of $0.34 million. TrovaGene had a negative net margin of 10,390.96% and a negative return on equity of 201.07%. View TrovaGene's Earnings History.

When will TrovaGene make its next earnings announcement?

TrovaGene is scheduled to release their next quarterly earnings announcement on Tuesday, November, 7th 2017. View Earnings Estimates for TrovaGene.

Where is TrovaGene's stock going? Where will TrovaGene's stock price be in 2017?

3 brokerages have issued 1 year target prices for TrovaGene's stock. Their forecasts range from $1.80 to $8.00. On average, they expect TrovaGene's share price to reach $4.60 in the next year. View Analyst Ratings for TrovaGene.

What are analysts saying about TrovaGene stock?

Here are some recent quotes from research analysts about TrovaGene stock:

  • 1. Maxim Group analysts commented, "Trovagene announced positive preclinical data for PCM-075, an oral polo-like kinase 1 (PLK1) inhibitor demonstrating synergy (80%) with a histone deacetylase (HDAC) inhibitor in aggressive double-hit non-Hodgkin lymphoma (NHL). B-cell lymphoma has the highest fold overexpression of PLK1 (56X)." (8/22/2017)
  • 2. Cantor Fitzgerald analysts commented, "The partnership with Boreal Genomics is an important milestone for the company, in our view. Per the long-term supply and distribution agreement, 1) TROV commits upfront and milestone payments totaling $1M, 2) TROV has global distribution rights in blood and exclusively in urine for least ten years, and 3) TROV and Boreal will form a joint effort to bring the assay kits and systems through the necessary regulatory pathways for approval. Importantly, TROV continues to target the analytical validation of its initial panel by the end of 2016 and plans to launch a series of cancer-specific multigene ctDNA urine and blood panels, in partnership with Boreal, in 2017. For more details on TROV’s commercialization strategy, please see our September 30, 2016 note. The OnTarget platform separates target mutations from the wild-type. In a one-hour process, the sample is injected into a gel matrix containing short oligo probes that are complementary to the target mutations. The temperature is increased to the melting temperature of the target-probe duplex and target mutations are separated by repeated hybridization in an alternating electric field. Target alleles are collected in the extraction chamber, while the wild-type is removed with more than 1M fold enrichment (and as high as 10M fold)." (11/30/2016)

Who are some of TrovaGene's key competitors?

Who are TrovaGene's key executives?

TrovaGene's management team includes the folowing people:

  • Thomas H. Adams Jr. Ph.D., Chairman of the Board
  • William J. Welch, Chief Executive Officer, Director
  • Athena M. Countouriotis M.D., Director
  • Paul R. Billings M.D., Ph.D., Independent Director
  • John P. Brancaccio CPA, Independent Director
  • Gary S. Jacob Ph.D., Independent Director
  • Rodney S. Markin M.D., Ph.D., Independent Director

Who owns TrovaGene stock?

TrovaGene's stock is owned by many different of retail and institutional investors. Top institutional shareholders include CVI INVESTMENTS, INC. (5.70%). Company insiders that own TrovaGene stock include Mark Erlander, Stanley Tennant and William J Welch. View Institutional Ownership Trends for TrovaGene.

How do I buy TrovaGene stock?

Shares of TrovaGene can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is TrovaGene's stock price today?

One share of TrovaGene stock can currently be purchased for approximately $0.81.


MarketBeat Community Rating for TrovaGene (NASDAQ TROV)
Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  190 (Vote Outperform)
Underperform Votes:  101 (Vote Underperform)
Total Votes:  291
MarketBeat's community ratings are surveys of what our community members think about TrovaGene and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for TrovaGene (NASDAQ:TROV) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: $4.60 (471.43% upside)
Consensus Price Target History for TrovaGene (NASDAQ:TROV)
Price Target History for TrovaGene (NASDAQ:TROV)
Analysts' Ratings History for TrovaGene (NASDAQ:TROV)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/18/2017Maxim GroupSet Price TargetBuy$4.00N/AView Rating Details
8/8/2017Cantor FitzgeraldReiterated RatingOverweightHighView Rating Details
3/16/2017Piper Jaffray CompaniesDowngradeNeutral -> UnderweightHighView Rating Details
3/10/2017S&P Equity ResearchBoost Price Target$1.55 -> $1.80N/AView Rating Details
5/12/2016Leerink SwannReiterated RatingHoldN/AView Rating Details
4/28/2016ArgusDowngradeBuy -> HoldN/AView Rating Details
3/29/2016Avondale PartnersReiterated RatingMarket Perform$6.00N/AView Rating Details
3/11/2016Janney Montgomery ScottDowngradeBuy -> NeutralN/AView Rating Details
2/22/2016Jefferies Group LLCReiterated RatingBuyN/AView Rating Details
(Data available from 10/22/2015 forward)

Earnings

Earnings History for TrovaGene (NASDAQ:TROV)
Earnings by Quarter for TrovaGene (NASDAQ:TROV)
Earnings History by Quarter for TrovaGene (NASDAQ TROV)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017($0.14)N/AView Earnings Details
5/10/2016Q116($0.29)($0.36)$0.34 million$0.12 millionViewListenView Earnings Details
3/10/2016Q415($0.25)($0.26)$0.14 million$0.08 millionViewListenView Earnings Details
8/10/2015Q215($0.24)($0.41)$0.05 millionViewListenView Earnings Details
5/5/2015($0.23)($0.24)$0.08 million$0.13 millionViewN/AView Earnings Details
3/12/2015Q414($0.26)($0.25)$0.06 millionViewN/AView Earnings Details
11/6/2014Q3 14($0.25)($0.28)$0.05 million$0.06 millionViewN/AView Earnings Details
8/7/2014($0.24)($0.18)$0.05 million$0.06 millionViewN/AView Earnings Details
5/12/2014($0.23)($0.17)$0.05 million$0.11 millionViewN/AView Earnings Details
3/17/2014Q413($0.19)($0.05)$0.15 million$0.05 millionViewN/AView Earnings Details
11/14/2013Q313($0.22)($0.25)ViewN/AView Earnings Details
8/14/2013Q213($0.15)($0.34)ViewN/AView Earnings Details
5/14/2013Q113($0.09)($0.07)$0.03 million$0.12 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for TrovaGene (NASDAQ:TROV)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for TrovaGene (NASDAQ:TROV)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for TrovaGene (NASDAQ:TROV)
Insider Ownership Percentage: 7.40%
Institutional Ownership Percentage: 8.94%
Insider Trades by Quarter for TrovaGene (NASDAQ:TROV)
Institutional Ownership by Quarter for TrovaGene (NASDAQ:TROV)
Insider Trades by Quarter for TrovaGene (NASDAQ:TROV)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/5/2017Stanley TennantDirectorSell8,334$0.69$5,750.46View SEC Filing  
12/19/2016Stanley TennantDirectorBuy10,000$2.10$21,000.00View SEC Filing  
12/16/2016Stanley TennantDirectorBuy14,966$2.00$29,932.00View SEC Filing  
12/16/2016William J WelchCEOBuy4,750$2.09$9,927.50View SEC Filing  
12/14/2016Mark ErlanderInsiderBuy5,000$2.08$10,400.00View SEC Filing  
8/12/2015Antonius SchuhCEOBuy20,000$5.45$109,000.00View SEC Filing  
8/12/2015Stanley TennantDirectorBuy10,000$6.06$60,600.00View SEC Filing  
8/12/2015Steve ZaniboniCFOBuy15,000$5.43$81,450.00View SEC Filing  
7/17/2015Bridger Management, LlcMajor ShareholderBuy140,000$8.75$1,225,000.00View SEC Filing  
4/2/2015Bridger Management, LlcMajor ShareholderBuy300,000$6.90$2,070,000.00View SEC Filing  
2/27/2015Bridger Management, LlcMajor ShareholderBuy263,286$5.36$1,411,212.96View SEC Filing  
2/6/2015Bridger Management, LlcMajor ShareholderBuy444,444$4.50$1,999,998.00View SEC Filing  
6/9/2014Steve ZaniboniCFOBuy6,329$3.95$24,999.55View SEC Filing  
9/3/2013Thomas Phd AdamsDirectorSell19,200$8.19$157,248.00View SEC Filing  
11/30/2012Stanley TennantDirectorBuy25,000$4.82$120,500.00View SEC Filing  
8/20/2012Gabriel CerroneDirectorBuy7,800$2.35$18,330.00View SEC Filing  
8/16/2012Gabriel CerroneDirectorBuy15,000$2.24$33,600.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for TrovaGene (NASDAQ:TROV)
Latest Headlines for TrovaGene (NASDAQ:TROV)
Source:
Loading headlines, please wait.

Social

Chart

TrovaGene (TROV) Chart for Sunday, October, 22, 2017

This page was last updated on 10/22/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.